SEMINAR: "Relaxin Family Peptide Receptors; Unusual GPCRs with unique challenges for therapeutic targeting"

Ross Bathgate is the leader of the Neuropeptides division at the Florey Neuroscience Institutes in Melbourne. He is a National Health and Medical Research Council (NHMRC) Senior Research Fellow and an Honorary Associate Professor in the Department of Biochemistry and Molecular Biology at the University of Melbourne. His work focuses on the relaxin family peptides and their G-protein coupled receptors. These peptide-receptor systems show enormous potential for therapeutic targeting and relaxin is currently in Phase III clinical trials for the treatment of acute heart failure. His work has attracted funding from the NHMRC, ARC and other Australian funding bodies as well as pharmaceutical companies (Johnson and Johnson, Takeda Cambridge, Corthera).